New antibiotics for selective treatment of gastrointestinal infection caused by Clostridium difficile.
作者： Alan P Johnson
DOI: 10.1517/13543776.2010.511177
关键词: Vancomycin 、 Fidaxomicin 、 Clostridium difficile 、 Oritavancin 、 Phases of clinical research 、 Antibiotics 、 Biology 、 Nitazoxanide 、 Metronidazole 、 Internal medicine 、 Microbiology
摘要: Importance of the field: Clostridium difficile infection (CDI) is associated with consumption antibiotics which disrupt normal microbial flora gut, allowing C. to establish itself and produce disease. Currently, only vancomycin or metronidazole are recommended for treatment many patients suffer from relapse on infection. Hence, there a need new options.Areas covered in this review: This review evaluates five agents development where focus CDI.What reader will gain: gives up-to-date information fidaxomicin, REP3123, oritavancin, NVB302 nitazoxanide their likelihood being licensed CDI.Take home message: One agent, has undergone Phase III clinical trials show it be promising agent CDI low rate relapse. Nitazoxanide parasitic intestinal infections but not CDI. However, small scale...
cabdirect.org
informahealthcare.com参考文章(33)
Michael John Dawson, Sjoerd Nicolaas Wadman, Jesus Cortes Bargallo, The use of type-b lantibiotic-based compounds having antimicrobial activity ,(2008)
I. A. Critchley, L. S. Green, C. L. Young, J. M. Bullard, R. J. Evans, M. Price, T. C. Jarvis, J. W. Guiles, N. Janjic, U. A. Ochsner, Spectrum of activity and mode of action of REP3123, a new antibiotic to treat Clostridium difficile infections Journal of Antimicrobial Chemotherapy. ,vol. 63, pp. 954- 963 ,(2009) , 10.1093/JAC/DKP041
D.M. Citron, F. Babakhani, E.J.C. Goldstein, K. Nagaro, S. Sambol, P. Sears, Y.-K. Shue, D.N. Gerding, Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection Anaerobe. ,vol. 15, pp. 234- 236 ,(2009) , 10.1016/J.ANAEROBE.2009.09.005
Sydney M. Finegold, Denise Molitoris, Marja-Liisa Vaisanen, Yuli Song, Chengxu Liu, Mauricio Bolaños, In vitro activities of OPT-80 and comparator drugs against intestinal bacteria. Antimicrobial Agents and Chemotherapy. ,vol. 48, pp. 4898- 4902 ,(2004) , 10.1128/AAC.48.12.4898-4902.2004
Fred C Tenover, L Clifford McDonald, Vancomycin-resistant staphylococci and enterococci: epidemiology and control. Current Opinion in Infectious Diseases. ,vol. 18, pp. 300- 305 ,(2005) , 10.1097/01.QCO.0000171923.62699.0C
Stuart Johnson, Recurrent Clostridium difficile infection: A review of risk factors, treatments, and outcomes Journal of Infection. ,vol. 58, pp. 403- 410 ,(2009) , 10.1016/J.JINF.2009.03.010
William R. Jarvis, JoAnn Schlosser, Ashley A. Jarvis, Raymond Y. Chinn, National point prevalence of Clostridium difficile in US health care facility inpatients, 2008 American Journal of Infection Control. ,vol. 37, pp. 263- 270 ,(2009) , 10.1016/J.AJIC.2009.01.001
R N Swanson, D J Hardy, N L Shipkowitz, C W Hanson, N C Ramer, P B Fernandes, J J Clement, In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile. Antimicrobial Agents and Chemotherapy. ,vol. 35, pp. 1108- 1111 ,(1991) , 10.1128/AAC.35.6.1108
U. A. Ochsner, S. J. Bell, A. L. O'Leary, T. Hoang, K. C. Stone, C. L. Young, I. A. Critchley, N. Janjic, Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model Journal of Antimicrobial Chemotherapy. ,vol. 63, pp. 964- 971 ,(2009) , 10.1093/JAC/DKP042
James A Karlowsky, Nancy M Laing, George G Zhanel, None, In Vitro Activity of OPT-80 Tested against Clinical Isolates of Toxin-Producing Clostridium difficile Antimicrobial Agents and Chemotherapy. ,vol. 52, pp. 4163- 4165 ,(2008) , 10.1128/AAC.00476-08